Prostate Cancer
New Approaches to Immunotherapy for Metastatic Castration-Resistant Prostate Cancer
H&O What are the relevant mutations or other alterations that molecular profiling can pick up in colorectal cancer, and how common are they? HH The […]
H&O What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR […]
H&O What is the KRAS G12C mutation? DH RAS mutations are one of the most common mutations in cancer (after the P53 mutation). Estimates suggest […]
Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]
A Review of Selected Presentations From the XVIII iwCLL • September 20-23, 2019 • Edinburgh, Scotland Ibrutinib Versus Placebo in Patients With Asymptomatic, Treatment-Naive Early-Stage Chronic […]
Abstract: Anticoagulants are used in several settings to reduce the risk of thromboembolic events, but they can be associated with severe complications, such as potentially fatal bleeding. […]
A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Brentuximab Vedotin With Chemotherapy for Stage 3/4 […]
Abstract: Hemophilia A and B are inherited bleeding disorders characterized by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and […]
H&O How is erythrocytosis defined? JP Erythrocytosis is the presence of too many red blood cells. Several different parameters are used to diagnose erythrocytosis in […]
Abstract: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and […]